Vir Biotechnology named Brent Sabatini, the company’s senior vice president and chief accounting officer, as interim principal financial officer following the departure of Jason O’Byrne, who will stay through August 3 to ensure a smooth transition while a permanent CFO is sought. Sabatini, who has more than two decades of finance and accounting experience and previously led finance roles at Capsida Biotherapeutics and Amgen, will oversee financial operations during the CFO transition. The company has launched a comprehensive search for a permanent CFO, underscoring the importance of stable financial leadership as Vir advances its infectious disease and cancer therapies. Executives, including CEO Marianne De Backer, emphasized confidence in the finance team during the leadership change. The announcements frame the move as a strategic continuity measure aimed at supporting ongoing clinical development and capital management amid a competitive biotechnology environment.